Researchers at the Department of Cell and Molecular Biology, Karolinska Institutet have captured the first detailed molecular ...
No matter where cancer cells grow in the human body, they are a threat to our health and our lives. But instead of treating ...
A new study identifies a mechanism for how COVID vaccines may, in infrequent cases, drive heart inflammation, a condition ...
RFdiffusion2, RFdiffusion3, and Riff-Diff each solve different structural problems in computational enzyme design ...
Spatial RNA medicine combines transcriptomics and RNA therapeutics, mapping gene expression in tissues to enhance precision ...
The seasonal vaccines market is entering a strong growth phase, projected to generate substantial revenues between 2025 and ...
Acuitas Therapeutics, a leader in lipid nanoparticle (LNP) delivery systems, has announced the publication of a new study in Nature Biomedical Engineering, titled "Spatial profiling of gene editing by ...
A new review in Chinese Medical Journal details progress in nanocarrier-based cancer therapy. It analyzes polymeric, lipidic, ...
In a Phase 3 trial of more than 18,000 volunteers across three countries, an mRNA influenza vaccine from Pfizer has outperformed standard seasonal flu shots by 34.5%. It's yet another sign that this ...
Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. Of 9,225 ...
Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published Wednesday in the New England Journal of Medicine. The vaccine uses the same ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback